{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:36:19Z","timestamp":1777869379906,"version":"3.51.4"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00108-026-02064-x","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T07:19:18Z","timestamp":1772435958000},"page":"539-548","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Update zur hypertrophen Kardiomyopathie","Update on hypertrophic cardiomyopathy"],"prefix":"10.1007","volume":"67","author":[{"given":"Andreas J.","family":"Rieth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Seidler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"issue":"37","key":"2064_CR1","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","volume":"44","author":"E Arbelo","year":"2023","unstructured":"Arbelo\u00a0E, Protonotarios\u00a0A, Gimeno\u00a0JR, Arbustini\u00a0E, Barriales-Villa\u00a0R, Basso\u00a0C et\u00a0al (2023) 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J Qual Care Clin Outcomes 44(37):3503\u20133626. https:\/\/doi.org\/10.1093\/eurheartj\/ehad194","journal-title":"European heart journal"},{"issue":"23","key":"2064_CR2","doi-asserted-by":"publisher","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","volume":"149","author":"SR Ommen","year":"2024","unstructured":"Ommen\u00a0SR, Ho\u00a0CY, Asif\u00a0IM, Balaji\u00a0S, Burke\u00a0MA, Day\u00a0SM et\u00a0al (2024) 2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation 149(23):e1239\u2013e311. https:\/\/doi.org\/10.1161\/CIR.0000000000001250","journal-title":"Circulation"},{"key":"2064_CR3","doi-asserted-by":"crossref","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et\u00a0al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European heart journal. 2021. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368.","DOI":"10.1093\/eurheartj\/ehab368"},{"issue":"9","key":"2064_CR4","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1002\/ejhf.2997","volume":"25","author":"B Moura","year":"2023","unstructured":"Moura\u00a0B, Aimo\u00a0A, Al-Mohammad\u00a0A, Keramida\u00a0K, Ben Gal\u00a0T, Dorbala\u00a0S et\u00a0al (2023) Diagnosis and management of patients with left ventricular hypertrophy: Role of multimodality cardiac imaging. A scientific statement of the Heart Failure Association of the European Society of Cardiology. ESC Heart Fail 25(9):1493\u20131506. https:\/\/doi.org\/10.1002\/ejhf.2997","journal-title":"European journal of heart failure"},{"key":"2064_CR5","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.m2024.0196","author":"MN Mobius-Winkler","year":"2024","unstructured":"Mobius-Winkler\u00a0MN, Laufs\u00a0U, Lenk\u00a0K (2024) The Diagnosis and Treatment of Hypertrophic Cardiomyopathy. Dtsch Arztebl Int. https:\/\/doi.org\/10.3238\/arztebl.m2024.0196","journal-title":"Dtsch Arztebl Int"},{"key":"2064_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s12181-023-00653-w","author":"R Pfister","year":"2023","unstructured":"Pfister\u00a0R, Hagenacker\u00a0T, Heemann\u00a0U, Hegenbart\u00a0U, Heidecker\u00a0B, Kruck\u00a0S et\u00a0al (2023) Versorgung von Patienten mit kardialer Amyloidose. Die Kardiologie. https:\/\/doi.org\/10.1007\/s12181-023-00653-w","journal-title":"Die Kardiologie"},{"issue":"20","key":"2064_CR7","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","volume":"390","author":"MS Maron","year":"2024","unstructured":"Maron\u00a0MS, Masri\u00a0A, Nassif\u00a0ME, Barriales-Villa\u00a0R, Arad\u00a0M, Cardim\u00a0N et\u00a0al (2024) Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. The New England journal of medicine 390(20):1849\u20131861. https:\/\/doi.org\/10.1056\/NEJMoa2401424","journal-title":"The New England journal of medicine"},{"issue":"10253","key":"2064_CR8","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","volume":"396","author":"I Olivotto","year":"2020","unstructured":"Olivotto\u00a0I, Oreziak\u00a0A, Barriales-Villa\u00a0R, Abraham\u00a0TP, Masri\u00a0A, Garcia-Pavia\u00a0P et\u00a0al (2020) Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 396(10253):759\u2013769. https:\/\/doi.org\/10.1016\/S0140-6736(20)31792-X","journal-title":"Lancet"},{"issue":"47","key":"2064_CR9","doi-asserted-by":"publisher","first-page":"5071","DOI":"10.1093\/eurheartj\/ehae579","volume":"45","author":"P Garcia-Pavia","year":"2024","unstructured":"Garcia-Pavia\u00a0P, Oreziak\u00a0A, Masri\u00a0A, Barriales-Villa\u00a0R, Abraham\u00a0TP, Owens\u00a0AT et\u00a0al (2024) Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy. Eur Heart J Qual Care Clin Outcomes 45(47):5071\u20135083. https:\/\/doi.org\/10.1093\/eurheartj\/ehae579","journal-title":"European heart journal"},{"key":"2064_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13071619","author":"H Savsin","year":"2025","unstructured":"Savsin\u00a0H, Tokarek\u00a0T (2025) Comprehensive Review: Mavacamten and Aficamten in Hypertrophic Cardiomyopathy. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines13071619","journal-title":"Biomedicines"},{"issue":"2","key":"2064_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","volume":"80","author":"MY Desai","year":"2022","unstructured":"Desai\u00a0MY, Owens\u00a0A, Geske\u00a0JB, Wolski\u00a0K, Naidu\u00a0SS, Smedira\u00a0NG et\u00a0al (2022) Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy. JACC Adv 80(2):95\u2013108. https:\/\/doi.org\/10.1016\/j.jacc.2022.04.048","journal-title":"Journal of the American College of Cardiology"},{"issue":"11","key":"2064_CR12","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/eurheartj\/ehae811","volume":"46","author":"E Gonzalez-Lopez","year":"2025","unstructured":"Gonzalez-Lopez\u00a0E, Maurer\u00a0MS, Garcia-Pavia\u00a0P (2025) Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine. Eur Heart J Qual Care Clin Outcomes 46(11):999\u20131013. https:\/\/doi.org\/10.1093\/eurheartj\/ehae811","journal-title":"European heart journal"},{"issue":"1","key":"2064_CR13","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","volume":"142","author":"MM Kittleson","year":"2020","unstructured":"Kittleson\u00a0MM, Maurer\u00a0MS, Ambardekar\u00a0AV, Bullock-Palmer\u00a0RP, Chang\u00a0PP, Eisen\u00a0HJ et\u00a0al (2020) Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation 142(1):e7\u2013e22. https:\/\/doi.org\/10.1161\/CIR.0000000000000792","journal-title":"Circulation"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-026-02064-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-026-02064-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-026-02064-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:38:01Z","timestamp":1777556281000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-026-02064-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2064"],"URL":"https:\/\/doi.org\/10.1007\/s00108-026-02064-x","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"31 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autorinnen und Autoren sowie die Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"A. Rieth:\n                      A.\u00a0Finanzielle Interessen: Stiftung William G.\u00a0Kerckhoff, zweckgebundene Forschungsf\u00f6rderung, verwaltet durch die Kerckhoff-Klinik.\u00a0\u2013 Votragshonorare: AstraZeneca, Bayer, Corvia Medical, Alnylam.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellter Kardiologe in der Kerckhoff-Klinik, Bad Nauheim\u00a0| Mitgliedschaften: DGK, ESC, ISHLT, DTG.\n                      T.\u00a0Seidler:\n                      A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: DFG, DZHK.\u00a0\u2013 Vortragshonorare oder Reisekostenerstattungen: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Corvia, Cytogenetics, Edwards Life Sciences, Medtronic, Myocardia, Novartis, Pfizer.\u00a0\u2013 Bristol Myers Squibb, Cytogenetics, Edwards Lifesciences.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Ltd. OA, Stv. Direktor, Kerckhoff Klinik Bad Nauheim.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autorinnen und Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf\n                      \n                      .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}